Medical devices, healthcare technology and the business of care
510(k) clearance · K261543

Phasix ST Parastomal Hernia Mesh

Davol, Inc., A Subsidiary of C.R. Bard, Inc. · Decision date Sep 28, 2026

MEDTECHLEDGER EXPLANATIONK261543

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on September 28, 2026 for Phasix ST Parastomal Hernia Mesh, submitted by Davol, Inc., a subsidiary of C.R. Bard, Inc., under K261543. The device is a sterile, single-use, prescription-only surgical mesh of bioabsorbable poly-4-hydroxybutyrate co-knitted with polyglycolic acid fibers, coated on the PGA surface with an absorbable HA/CMC/PEG hydrogel; the submission states the mesh materials are identical in composition to the reference device, Phasix ST Mesh (K143380). The listed predicate is BioDesign Parastomal Hernia Repair Graft (K162934).

The stated indication is reinforcement of soft tissue where weakness exists in procedures for repair of parastomal hernias. The clearance covers the device as described in the 510(k) summary; it is not a PMA approval. The summary does not provide clinical outcome data, and the source does not state a review of long-term performance in patients, so any such assessment remains unknown.

The record lists regulation 21 CFR 878.3300, Class II, product codes OWT, OOD and FTL, with a General and Plastic Surgery specialty; the application was received May 8, 2026.

Regulatory pathway
510(k) premarket notification
Clinical specialty
General, Plastic Surgery
Decision date
Sep 28, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261543
Regulatory pathway
510(k) premarket notification
Product code
OWT
Decision code
SESE
Decision date
Sep 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Mesh, Surgical, Absorbable, Abdominal Hernia.

Product code
OWT
FDA device class
2

FDA decision timeline

  1. K261543 received

    Application receipt date recorded by FDA.

  2. K261543 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code OWT

Product / regulatory recordCompanyPathwayDecision dateSource
Sofradim Production510(k) clearanceOct 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Davol, Inc., A Subsidiary of C.R. Bard, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Warwick, RI

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records